Rituximab-induced serum sickness in multiple sclerosis patients.

Autor: Wolf AB; Department of Neurology, University of Colorado School of Medicine, 12631 East 17th Avenue, Aurora, CO 80045 USA. Electronic address: andrew.wolf@ucdenver.edu., Ryerson LZ; New York University Multiple Sclerosis Comprehensive Care Center, 240 East 38th Street, New York, NY 10016 USA., Pandey K; Hackensack University Medical Center, 30 Prospect Avenue, Hackensack, NJ 07061 USA., McGettigan BM; Department of Medicine, University of Southern California Keck School of Medicine, 1975 Zonal Avenue, Los Angeles, CA 90033 USA., Vollmer T; Department of Neurology, University of Colorado School of Medicine, 12631 East 17th Avenue, Aurora, CO 80045 USA; Rocky Mountain Multiple Sclerosis Center, 12631 East 17th Avenue, Aurora, CO 80045 USA., Corboy JR; Department of Neurology, University of Colorado School of Medicine, 12631 East 17th Avenue, Aurora, CO 80045 USA; Rocky Mountain Multiple Sclerosis Center, 12631 East 17th Avenue, Aurora, CO 80045 USA., Alvarez E; Department of Neurology, University of Colorado School of Medicine, 12631 East 17th Avenue, Aurora, CO 80045 USA; Rocky Mountain Multiple Sclerosis Center, 12631 East 17th Avenue, Aurora, CO 80045 USA. Electronic address: enrique.alvarez@ucdenver.edu.
Jazyk: angličtina
Zdroj: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2019 Nov; Vol. 36, pp. 101402. Date of Electronic Publication: 2019 Sep 17.
DOI: 10.1016/j.msard.2019.101402
Abstrakt: Rituximab is a chimeric anti-CD20 monoclonal antibody that is an effective therapy for multiple sclerosis. Rituximab has been associated with the development of serum sickness (type III hypersensitivity) characterized by arthralgia, fever, and rash during the treatment of other conditions, such as rheumatoid arthritis. Here we describe serum sickness associated with rituximab in multiple sclerosis patients and discuss both the management of serum sickness itself and implications for utilizing alternative anti-CD20 monoclonal antibodies for disease management in this patient population.
(Copyright © 2019 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: